162 related articles for article (PubMed ID: 20413898)
1. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer's disease.
Kester MI; van der Flier WM; Mandic G; Blankenstein MA; Scheltens P; Muller M
J Alzheimers Dis; 2010; 20(4):1083-90. PubMed ID: 20413898
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
3. CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.
Kester MI; Blankenstein MA; Bouwman FH; van Elk EJ; Scheltens P; van der Flier WM
J Alzheimers Dis; 2009; 16(3):601-7. PubMed ID: 19276554
[TBL] [Abstract][Full Text] [Related]
4. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
5. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
6. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
7. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
8. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
9. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
10. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration.
Noguchi M; Yoshita M; Matsumoto Y; Ono K; Iwasa K; Yamada M
J Neurol Sci; 2005 Oct; 237(1-2):61-5. PubMed ID: 15992827
[TBL] [Abstract][Full Text] [Related]
11. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
12. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
14. ApoE alleles and tau markers in patients with different levels of cognitive impairment.
Lavados M; Farías G; Rothhammer F; Guillon M; Mujica MC; Maccioni C; Maccioni RB
Arch Med Res; 2005; 36(5):474-9. PubMed ID: 16099324
[TBL] [Abstract][Full Text] [Related]
15. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
[TBL] [Abstract][Full Text] [Related]
16. Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype.
Fagan AM; Younkin LH; Morris JC; Fryer JD; Cole TG; Younkin SG; Holtzman DM
Ann Neurol; 2000 Aug; 48(2):201-10. PubMed ID: 10939571
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
18. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal changes of CSF biomarkers in memory clinic patients.
Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
[TBL] [Abstract][Full Text] [Related]
20. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.
Motter R; Vigo-Pelfrey C; Kholodenko D; Barbour R; Johnson-Wood K; Galasko D; Chang L; Miller B; Clark C; Green R
Ann Neurol; 1995 Oct; 38(4):643-8. PubMed ID: 7574461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
